Patents by Inventor Lawrence I. Kruse

Lawrence I. Kruse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tryptamine analogues, their synthesis and their use as 5-HT.sub.1 -like or 5-HT.sub.2 receptor agonists
    Patent number: 5571833
    Abstract: The present invention relates to known and novel tryptamine analogues, processes and intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy, in particular for the treatment and/or prophylaxis of disorders characterized by excessive vasodilatation, such as migraine and portal hypertension.
    Type: Grant
    Filed: May 26, 1994
    Date of Patent: November 5, 1996
    Assignee: SmithKline Beecham plc
    Inventors: Lawrence I. Kruse, Rodney C. Young, Alberto J. Kaumann
  • Naphthyl-,tetrahydronaphthyl-, and indanyl-substituted G-em-diphosphonates and process of use to treat hyperlipidemia
    Patent number: 5204336
    Abstract: Substituted gem-diphosphonate compounds having use as cholesterol lowering agents are disclosed. A compound of the invention is tetraethyl-2-[3-t-butyl-4-hydroxynaphthyl]ethenylidene-1,1-diphosphonate.
    Type: Grant
    Filed: May 6, 1992
    Date of Patent: April 20, 1993
    Assignee: Symphar S.A.
    Inventors: Lawrence I. Kruse, Virendra P. Shah
  • 2-(substituted phenyl)-4-oxo-quinazolines
    Patent number: 5147875
    Abstract: This invention relates to quinazolinone derivatives which have bronchodilator activity. A compound of the invention is 2-(2-propoxyphenyl)quinazolin-4(3H)-one.
    Type: Grant
    Filed: November 30, 1989
    Date of Patent: September 15, 1992
    Assignee: Sanshin Kogyo Kabishiki Kaisha
    Inventors: William J. Coates, Lawrence I. Kruse
  • Dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4992459
    Abstract: Potent DBH inhibitors having the formula ##STR1## can be used to inhibit DBH activity in mammals.
    Type: Grant
    Filed: May 18, 1988
    Date of Patent: February 12, 1991
    Assignee: SmithKline Beecham Corporation
    Inventors: Joseph A. Finkelstein, James S. Frazee, Carl Kaiser, Lawrence I. Kruse, Thomas B. Leonard
  • Dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4935438
    Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals.
    Type: Grant
    Filed: December 29, 1987
    Date of Patent: June 19, 1990
    Assignee: SmithKline Beckman Corporation
    Inventors: Lawrence I. Kruse, Stephen T. Ross, Eliot H. Ohlstein
  • Intermediate to dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4912226
    Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
    Type: Grant
    Filed: September 15, 1989
    Date of Patent: March 27, 1990
    Assignee: SmithKline Beckman Corporation
    Inventors: Lawrence I. Kruse, Stephen T. Ross, Eliot H. Ohlstein
  • 2-(aminoalkylthio)imidazoles as dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4882348
    Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mannals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
    Type: Grant
    Filed: December 29, 1987
    Date of Patent: November 21, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Lawrence I. Kruse, Stephen T. Ross, Eliot H. Ohlstein
  • 1-aralkyl-2-mercaptoimidazolines as DBH inhibitors
    Patent number: 4876266
    Abstract: Disclosed are novel substituted 3-aralkylimidazolines of the structure. ##STR1## processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy in particular as dopamine-.beta.-hydroxylase inhibitors.
    Type: Grant
    Filed: December 31, 1987
    Date of Patent: October 24, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Lawrence I. Kruse, Thomas B. Leonard, Stephen T. Ross
  • Trifluoro acetyl-cyano-aniline intermediates for dopamine-.beta.hydroxylase inhibitors
    Patent number: 4873357
    Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula: ##STR1## which are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
    Type: Grant
    Filed: October 8, 1987
    Date of Patent: October 10, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Carl Kaiser, Lawrence I. Kruse, Stephen T. Ross
  • Heterocyclic compounds
    Patent number: 4861773
    Abstract: The invention relates to thiadiazinone derivatives that have utility as cardiac stimulants. A compound of the invention is 7-(1H-imidazol-1-yl)-9,9a-dihydroindeno[1,2-e][1,3,4]-thiadiazin-2(3H)-one .
    Type: Grant
    Filed: January 29, 1988
    Date of Patent: August 29, 1989
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: William J. Coates, Lawrence I. Kruse
  • Dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4859779
    Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
    Type: Grant
    Filed: January 27, 1989
    Date of Patent: August 22, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Joseph A. Finkelstein, Lawrence I. Kruse, Thomas B. Leonard
  • Dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4857540
    Abstract: 1-substituted-2-mercapto(or aminomethyl)benzimidazole compounds which inhibit dopamine-.beta.-hydroxylase activity.
    Type: Grant
    Filed: November 27, 1987
    Date of Patent: August 15, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Carl Kaiser, Lawrence I. Kruse
  • 3-aralkyl-2-mercaptoyridines as dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4839371
    Abstract: Disclosed are novel substituted 3-aralkyl-2-mercaptopyridines of the structure: ##STR1## processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy in particular as dopamine-.beta.-hydroxylase inhibitors.
    Type: Grant
    Filed: September 17, 1987
    Date of Patent: June 13, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Lawrence I. Kruse, Stephen T. Ross
  • Dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4837353
    Abstract: 2-(N-Phenylakyl-N-formyl)amino-3-hydroxy-2-propenoic acids are intermediates for mercaptoimidazolecarboxylic acids which are dopamine-.beta.-hydroxylase inhibitors.
    Type: Grant
    Filed: January 21, 1988
    Date of Patent: June 6, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Joseph A. Finkelstein, Lawrence I. Kruse, Thomas B. Leonard
  • 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-.beta.hydroxylase inhibitors
    Patent number: 4835154
    Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
    Type: Grant
    Filed: June 1, 1987
    Date of Patent: May 30, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Joseph A. Finkelstein, Lawrence I. Kruse
  • Dopamine-beta-hydroxylase inhibitors
    Patent number: 4810811
    Abstract: The compounds of this invention are 1-phenylalkyl-2-mercaptotetrazole compounds which are dopamine-.beta.-hydroxylase inhibitors.
    Type: Grant
    Filed: August 24, 1987
    Date of Patent: March 7, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Carl Kaiser, Lawrence I. Kruse
  • 2-mercaproimidazole dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4798843
    Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutial compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
    Type: Grant
    Filed: July 9, 1987
    Date of Patent: January 17, 1989
    Assignee: SmithKline Beckman Corporation
    Inventor: Lawrence I. Kruse
  • Dopamine .beta.-hydroxylase inhibitors
    Patent number: 4772723
    Abstract: Potent DBH Inhibitors having the formula: ##STR1## wherein R is --CO.sub.2 H or --CH.sub.2 NHR.sup.1 can be used to inhibit DBH activity in mammals.
    Type: Grant
    Filed: April 16, 1985
    Date of Patent: September 20, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: James S. Frazee, Carl Kaiser, Lawrence I. Kruse
  • Substituted tetrahydro isoquinoline intermediates
    Patent number: 4767862
    Abstract: Compounds having the formula ##STR1## are .beta.-adrenergic receptor antagonists. Also disclosed are pharmaceutical compositions and methods for producing .beta.-adrenergic receptor antagonistic activity in animals including man.
    Type: Grant
    Filed: August 24, 1987
    Date of Patent: August 30, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: Carl Kaiser, Lawrence I. Kruse
  • Dopamine-beta-hydroxylase inhibitors
    Patent number: 4762850
    Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
    Type: Grant
    Filed: March 24, 1987
    Date of Patent: August 9, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: Joseph A. Finkelstein, Lawrence I. Kruse, Thomas B. Leonard